The isotrate dehydrogenase (IDH) inhibitors market sales is predicted to expand from US$ 1.7 billion in 2022 to US$ 39.16 billion in 2033, with a compound annual growth rate (CAGR) of 33% from 2023 to 2033. Additionally, the development of more potent and selective IDH inhibitors, as well as the expansion of their use into …